For decades, cannabis asked America for a leap of faith. Patients said it helped. Doctors said some responded. Advocates said prohibition did more damage than the plant. And government kept answering: show us the evidence.
This week, Minnesota showed some. The state’s Office of Cannabis Management analyzed 6,621 cancer patients enrolled in its medical program, tracking actual purchases, symptom ratings, and follow-up over time. The findings aren’t miraculous, and that’s exactly what makes them useful. Pain improved for a meaningful share. So did nausea, vomiting, appetite, sleep. Only 15 percent reported adverse effects, mostly mild.
That’s not proof cannabis cures anything. It’s something more durable: large-scale government data showing patients inside a regulated medical system often report real symptom relief. And it landed the same week the FDA laid out how to run psychedelic trials when everyone knows who got the real drug, Ohio started investigating serious health reports tied to vapes, and a Mississippi dispensary owner said the DEA gave her a choice between federal registration and two employees with old felony records. The industry doesn’t win anymore just by showing prohibition failed. Now it has to show regulated cannabis works better. Let me walk you through it.
Minnesota just gave medical cannabis the thing it always lacked: scale.
Minnesota’s Office of Cannabis Management analyzed data from 6,621 cancer patients in the state’s medical marijuana program, one of the largest studies ever conducted on medical cannabis treatment according to state officials. Researchers tracked purchases, self-evaluation surveys, symptom ratings, and side effects over time.
The numbers are worth walking through. Among the 82 percent who reported moderate-to-severe pain at enrollment, about 30 percent saw at least a 30 percent reduction in their pain score within four months of their first purchase, and more than half of those held that improvement for at least another four months. More than half of patients initially reported nausea and over a quarter reported vomiting, and after four months, 40 percent of the nausea group and 47 percent of the vomiting group reported at least a 30 percent reduction. Among responders, improvement persisted another four months for 65 percent with nausea and 74 percent with vomiting. Appetite improved by 30 percent or more for 38 percent of patients struggling with it, with nearly two-thirds holding that gain. Patients also reported improvements in anxiety, depression, sleep, and fatigue, though response rates varied a lot across those. And the safety signal: only 15 percent reported an adverse effect, 60 percent of which were mild.
Oncologist Dr. Dylan Zylla called it strong observational evidence that many cancer patients get better symptom control, and recommended the familiar approach of starting low on THC and increasing gradually. That word, observational, matters and I won’t gloss over it. This wasn’t randomized or placebo-controlled, patients knew they were using cannabis, they picked their own products, and symptoms were self-reported, so it can’t prove marijuana caused every improvement.
But dismissing it on those grounds misses the point. Cancer supportive care isn’t only about curing disease. Sometimes the outcome that matters is less pain, less nausea, better sleep, more appetite, or needing fewer other medications.
For businesses, government-generated evidence like this may matter more commercially than any consumer survey, because institutional healthcare doesn’t run on testimonials. Physicians want data, insurers want data, hospital systems want data, and lenders evaluating medical cannabis want some confidence that patient demand reflects an actual therapeutic use case rather than recreational spending routed through a medical channel. This strengthens that case considerably.
The bottom line: The most powerful thing here isn’t that cannabis “worked.” It’s that government now has enough real-world data to measure where it appears to work, how often, and for how long. That’s when medical cannabis becomes healthcare.
The FDA is solving the weirdest problem in psychedelic medicine: everyone knows they took it.
The FDA is tackling a question that sounds technical and may determine whether psychedelic therapies ever reach millions of patients. How do you evaluate a drug when the patient definitely knows they got it? Officials are outlining a new framework for psychedelic medicines, part of a broader administration push to move promising mental-health treatments through review faster, and the agency convened a public hearing on therapeutic uses this week.
Here’s the core problem. In a conventional antidepressant trial, one group gets the drug, one gets placebo, and ideally nobody knows which. Give someone psilocybin or MDMA and that assumption collapses within the hour, for both the patient and often the researchers watching. That’s called functional unblinding, and it muddies results because expectation itself can shape outcomes. So the FDA’s guidance puts unusual weight on trial design, active comparators, expectancy measurement, and procedures that acknowledge these drugs produce experiences ordinary medicines don’t.
Consent is the other piece. The guidance stresses that patients can experience changes in perception, cognition, and judgment lasting hours, which creates an unusual vulnerability window. This isn’t swallowing a pill and driving home. Who stays in the room matters, monitoring matters, what happens if the patient becomes distressed matters, and the therapeutic environment may itself influence outcomes.
This is what mature drug policy actually looks like: urgency plus controls. The FDA isn’t pretending psychedelics are normal pills. It’s making the approval pathway workable despite the fact that they aren’t.
The urgency is real too, with Trump’s executive order directing agencies to accelerate work on treatment-resistant mental illness and the FDA naming depression, PTSD, and substance-use disorders as priorities. That’s a dramatically different federal posture than a few years ago, when the conversation was about prohibition rather than clinical endpoints and manufacturing. But it’s a warning for investors: a promising molecule isn’t a business. If the therapy model requires trained clinicians, long sessions, special facilities, and follow-up, approval doesn’t automatically create scalable economics. A drug needing six or eight supervised hours behaves completely differently from a pill taken at home.
The bottom line: The winners here won’t just prove their drug works. They’ll prove the entire treatment system can work safely at scale.
An Ohio dispensary closed over vape health reports, and every word of this story matters.
An Ohio marijuana dispensary voluntarily closed after two customers reported serious adverse health effects following use of vape products purchased there. The Herbal Wellness Center in Jackson shut down at the request of Ohio’s Division of Cannabis Control while regulators investigate, and parent company Vext Sciences says it hasn’t seen substantiated evidence establishing that any of its products caused or contributed to either event.
I want to be precise here, because this is exactly the kind of story that gets distorted fast. A health event happened. Cannabis vapes are part of the investigation. Causation has not been established. Regulators collected product from the same lot as at least one item an affected customer purchased, and follow-up testing detected no harmful contaminants, with some products remaining on precautionary hold while testing continues. A person also died at a nearby emergency room within roughly five or six days of the closure, the coroner’s office sent the body for autopsy, and officials explicitly say the cause of death isn’t yet known and they don’t know whether it connects to the cannabis investigation at all.
A mature industry has to resist two equally dangerous instincts. Panic: a vape was involved, so the vape did it. And denial: testing found nothing, so there’s nothing to investigate. The correct answer is neither. It’s investigate.
Hold product, retest, review the medical evidence, trace the lot, communicate carefully, then decide. That’s how pharmaceutical safety works, and food safety, and it’s the price of institutional legitimacy. The broader lesson for the industry is that vapes are among the most technically complex cannabis categories, involving hardware, heating elements, oil formulations, terpenes, cartridge materials, and manufacturing processes that all add quality-control variables. A vape can hit its cannabinoid potency spec and still have a problem elsewhere, hardware failure, thermal degradation, trace metals, manufacturing residue. Which is why pre-market testing isn’t enough. Cannabis needs pharmacovigilance, post-market monitoring when adverse events occur, and right now it doesn’t have the nationwide infrastructure conventional pharma does, with states handling investigations individually. For banks and acquirers, safety systems belong in diligence now: can the operator trace a lot immediately, identify every location carrying the batch, hold product voluntarily, execute a recall quickly?
The bottom line: This investigation shouldn’t become evidence for or against cannabis until investigators know what happened. But it’s already evidence that legal cannabis needs serious post-market safety systems. Knowing what to do after a complaint may matter more than testing before the sale.
Congress gave hemp until December. Missouri said November anyway.
Hemp businesses just learned another hard lesson: Congress can give you more time, and your state doesn’t have to honor it. Missouri is still preparing to impose new restrictions on intoxicating hemp products starting November 12, even though the president signed federal legislation delaying most comparable federal restrictions to December 11. Under Missouri’s law, many products exceeding 0.4mg of THC per container get treated as marijuana and shifted into the state’s licensed cannabis system. THC beverages get a temporary reprieve, staying in conventional stores through December 11 under age-21 rules, and what happens after depends partly on Congress, with Missouri lawmakers possibly revisiting beverage rules in January if federal lawmakers create a separate framework.
Now picture running a beverage manufacturer inside that. You need to order cans, labels, ingredients, cartons, distribution inventory, and 2027 retail placements, and the legal answer depends on what Congress does in December and what Missouri does in January.
That’s not inconvenience. That’s working capital, packaging commitments, purchase orders, distribution agreements, debt-service forecasting, and inventory obsolescence, all hostage to two legislative calendars that don’t talk to each other.
Missouri’s framework effectively moves a range of products from ordinary retail into licensed marijuana channels, which makes the same physical product economically different overnight. A convenience-store item becomes dispensary inventory. A hemp manufacturer suddenly faces cannabis licensing. A retailer loses a revenue category and a licensed operator gains one. Consumers don’t necessarily disappear, the margin just moves. There’s also the recurring problem with per-container thresholds, since a high-CBD full-spectrum product can exceed 0.4mg across a whole bottle while being designed for wellness rather than intoxication. Supporters say clear limits simplify enforcement and reduce youth access, critics say they sweep too broadly, and both can be right. For lenders, this demands product-level underwriting: how much THC per serving and per container, naturally occurring or converted, which state, which channel, can it move into a dispensary, can the company reformulate, does revenue survive a federal ban, does it survive a state ban even if federal law loosens.
🎯 The bottom line: Hemp doesn’t have one regulatory deadline. It has dozens. Federal relief is useful, and state law can erase the benefit entirely. Regulatory diversification now matters almost as much as product diversification.
Massachusetts may test whether you can dismantle a market after $10 billion in sales.
Massachusetts voters face an unusually strange question in November. Not “should possession be illegal again,” but Question 8, which would repeal major portions of the regulated adult-use commercial system while leaving certain possession legal. The consumer keeps cannabis. The licensed marketplace supplying it largely disappears.
Flagging clearly that the case against Question 8 here comes from a Marijuana Moment op-ed by Steve Reilly of cannabis company Insa, so that’s industry advocacy, not neutral analysis. But the structural consequences are real. Massachusetts has built out cultivators, manufacturers, labs, retailers, security, technology, real estate, professional services, and municipal agreements since 2016, supporting roughly 27,000 jobs and around $300 million in annual state tax revenue, with cumulative adult-use sales past $10 billion.
Strip the commercial structure and leave possession legal, and you have to ask where the demand goes. Some consumers qualify medically, some grow at home, some drive out of state, some return to illicit sellers.
What’s not happening is billions of dollars of demonstrated demand quietly evaporating. Repeal after a market launches doesn’t just change criminal law. It unwinds operating companies, leases, loans, payroll, and supplier contracts.
For lenders, ballot risk becomes a genuine underwriting factor, which is extraordinary when you think about it. A Massachusetts dispensary can show historical cash flow, strong margins, good management, and clean compliance, and still face existential risk from a statewide vote. Ordinary retailers basically never face a ballot measure asking whether their sector should keep selling its core product. The safety argument matters too, since licensed products carry testing, labeling, packaging, and security requirements, and if regulated sales vanish while possession stays legal, demand migrates toward suppliers outside those controls. None of which proves the current system is optimal, because critics can point to real regulatory failures, market concentration, and local disputes. But fixing a system and deleting it are different choices.
The bottom line: Question 8 asks whether a state can keep legal consumption while dismantling legal commerce. If the answer is yes, the real question isn’t whether demand survives. It’s which market captures it.
Nebraska’s Supreme Court shut down another challenge. Now build the thing.
Nebraska voters approved medical cannabis. Opponents challenged it. Courts rejected them. They challenged it another way, and courts have now rejected that too. In a unanimous 29-page ruling, the Nebraska Supreme Court held that former state Sen. John Kuehn lacked standing to pursue a constitutional challenge, with Chief Justice Jeffrey Funke concluding he didn’t qualify under taxpayer standing or the state’s limited exception for matters of great public concern.
Kuehn’s underlying theory is worth understanding because of how far it reaches. He argues state medical marijuana systems are preempted by federal law under the Supremacy Clause, and if broadly accepted, that would threaten the foundation of nearly every state cannabis program in the country, since the entire modern system exists because the federal government largely tolerated the divergence. The court didn’t resolve that on the merits, it ruled on standing, and the dismissal was without prejudice, so a future challenge remains theoretically possible.
Still, every failed challenge adds political durability. Voters voted, a commission exists, the legislature appropriated funding, new legislation passed, and federal policy itself has shifted, with the administration moving state-licensed medical marijuana toward Schedule III, which makes a simple preemption argument considerably harder. Washington is no longer claiming state medical cannabis has no medical legitimacy.
But legal victory is stage one. Nebraska still needs licensing, cultivation, processing, testing, distribution, dispensaries, patient access, and banking. Every month spent litigating is a month the program isn’t useful to anyone.
That delay has real cost, prospective operators burning legal fees, real-estate options expiring, capital sitting idle, banks staying cautious, patients waiting. Which is why political certainty itself has financial value, and a market with mediocre rules but high durability can attract more capital than one with excellent rules under constant existential threat. Nebraska is drifting toward the durable column, and the next headlines from the state should be gloriously boring: license applications, testing standards, store openings, patient enrollment.
The bottom line: Nebraska has spent enormous institutional energy answering whether medical cannabis can exist. Voters and courts keep saying yes. Time to answer the question patients actually care about: when does it work?
RFK Jr. says the psychedelic bottleneck won’t be drugs. It’ll be people.
HHS Secretary Robert F. Kennedy Jr. is thinking about psychedelics like a healthcare administrator rather than an advocate, and his concern is what happens if the therapies work and everyone wants them. He says there could be “enormous demand” as access expands, especially among veterans, and speaking on an HHS podcast with Americans for Ibogaine CEO Bryan Hubbard, estimated some treatment models could require more than 100 hours of support staff time per veteran.
That number is startling, but the operational point underneath it matters more than the precise figure. Psychedelic medicine may be genuinely hard to scale, because the care is labor-intensive: preparation, medical screening, administration, monitoring, integration, follow-up, and potential crisis intervention. A psilocybin session can occupy a treatment room for many hours, staffing needs are significant, patient throughput is limited, and reimbursement suddenly matters nearly as much as efficacy.
Cannabis offers the cautionary tale here, because state medical programs routinely legalized access before the system was ready. Cards existed before enough dispensaries, dispensaries opened before enough product, cultivators launched before labs, companies got licenses without banking. Infrastructure chased legalization from behind the whole way.
Psychedelics have a chance to reverse that sequence. Build the workforce first, train clinicians, set supervision ratios, clarify liability, design reimbursement, establish adverse-event systems, then scale access. Boring, and exactly what healthcare requires.
For investors, this reframes valuation entirely. The most important asset may not be the molecule, it may be delivery capacity. A company with a promising drug and no efficient treatment protocol could struggle, while a clinic network with trained practitioners, appropriate real estate, insurance relationships, clean workflows, and documented outcomes could become enormously valuable without inventing anything. That looks more like oncology, dialysis, and infusion medicine than cannabis retail, constrained by staffing, rooms, credentials, payer contracts, and scheduling. Banks understand those economics, which means psychedelic therapy could become conventionally underwritable much faster than cannabis ever did.
The bottom line: The future shortage probably isn’t psilocybin or MDMA. It’s therapists, treatment rooms, and reimbursable clinical hours. If demand gets enormous, infrastructure is the investment thesis.
The DEA told a dispensary owner to choose between federal registration and two employees.
Cannabis wanted federal recognition. It’s now discovering federal recognition arrives with old federal rules attached. Nicole Huff, CEO of Wildflower Medical Dispensary in Aberdeen, Mississippi, says the DEA’s new medical-marijuana registration process could force her to choose between registration and two employees with felony convictions, both employed over a year without disciplinary problems. The DEA laid out her options: remove them, withdraw the application, seek employment waivers while giving up expedited processing, or let the application proceed toward an Order to Show Cause and possibly a hearing before an administrative law judge. Huff says she intends to fight for the workers.
The rule itself makes sense in conventional pharmaceutical regulation, since DEA rules generally bar registered controlled-substance businesses from employing people with certain controlled-substance felony convictions in roles with access to controlled drugs absent a waiver, weighing the offense, current licensing, degree of access, diversion safeguards, and the employer’s compliance history. A controlled-substance distributor carries real diversion risk.
But cannabis creates a paradox nobody designed for.
The industry is full of people prosecuted under the very laws now being rewritten. Social-equity frameworks explicitly prioritize hiring them. Then federal registration arrives and says that old cannabis conviction may block controlled-substance access.
The question isn’t whether the DEA should ignore criminal history. It’s whether the system can distinguish a recent diversion offense from serious trafficking misconduct from a years-old nonviolent cannabis conviction followed by stable employment. That’s precisely what a thoughtful waiver process should do, and if it works efficiently, federal compliance and second-chance employment can coexist. If it takes months, lawyers, and administrative hearings, employers will respond rationally by not hiring people with records at all, which becomes indirect exclusion. For banks, this is staffing and key-person risk, since a borrower getting DEA registration may have to restructure employment, and losing a cultivation manager or senior operator hurts operations. Registration brings legitimacy and oversight, but companies need to budget for background review, legal advice, waivers, training, and possible staffing changes. Expect hundreds more conflicts like this as registration expands to manufacturers, distributors, and labs.
The bottom line: Schedule III isn’t just a tax story. It’s a systems-integration story, where federal controlled-substance rules collide with state cannabis rules, equity goals, and real employees. The operators who navigate that will beat the ones who thought rescheduling just meant 280E disappears.
Minnesota’s cancer study may end up mattering more than a dozen legalization bills, for a simple reason: political arguments change, and data compounds.
The industry spent decades trapped in circular logic. Federal prohibition restricted research, then the resulting lack of research was used as proof cannabis had no accepted medical value. That loop is finally breaking, because state programs now hold hundreds of thousands of patient-years of experience, researchers can study real-world outcomes, and agencies can follow patients over time. And that won’t always flatter cannabis, which is the point. Some products will fail, some conditions will show no response, some patients will have side effects, and some commercial claims will turn out to be nonsense. Good. That’s medicine. The goal was never to prove cannabis helps everyone. It’s to find out who it helps enough to matter.
The FDA is applying the same philosophy to psychedelics, wanting promising therapies to move faster without pretending they behave like blood-pressure tablets. Ohio shows why those instincts matter, because a legitimate industry isn’t defined by the absence of adverse events. Food gets recalled, cars get recalled, drugs get recalled. What defines legitimacy is having systems to identify, investigate, and respond, which means cannabis needs cross-state adverse-event reporting, lot-level traceability, independent lab capacity, recall procedures, and crisis plans. All of it sounds boring until the phone rings and two customers are in the hospital. Missouri makes the regulatory version of the point: if your product exists only because Congress wrote a definition imperfectly in 2018, assume the definition can change. Massachusetts makes the political one: demand is durable, infrastructure is optional, and government can close legal stores without closing the market, which turns the whole debate into a single question, who do you want satisfying that demand?
Nebraska is reaching the stage where litigation matters less than construction, because legalization loses credibility when it produces three years of court fights and no usable patient access. And the DEA employment story may be the most revealing of all, since the Controlled Substances Act system was built for a world where legal cannabis businesses didn’t exist, state legalization built a completely different world, and now those systems are merging and grinding against each other. Every conflict forces regulators to decide whether an old rule still makes sense. That’s what normalization actually means, not waving away regulation but modernizing it. Cannabis spent decades arguing from values, freedom, compassion, criminal justice, medical access, and those arguments built the movement. The next phase gets won with patient outcomes, safety data, lab results, financial statements, and regulatory performance. The industry finally has the chance to stop asking America to believe it, and start proving the case.
That’s what this newsletter is for.
What’s the biggest regulatory challenge your operation is facing right now? Hit reply, I read every response and it shapes what I cover next week.
If this was useful, forward it to someone in the cannabis space or hit the restack button on Substack. It’s how this community grows.